Boehringer establishes new biomass production in Germany
CO2 emissions produced by the energy generated at Boehringer Ingelheim's site are reduced by over half with the new biomass power plant.
List view / Grid view
CO2 emissions produced by the energy generated at Boehringer Ingelheim's site are reduced by over half with the new biomass power plant.
The paper describes an innovative ion chromatography-based analytical method for quantifying nitrite quantities in purified and potable water.
The acquisition, which has a value of approximately $3.2 billion, is set to support development of small molecule oral integrin therapies for conditions such as ulcerative colitis.
The Association of the British Pharmaceutical Industry (ABPI) and Drug Research Safety Unit (DRSU) assert the importance of partnership and collaboration to support the pharmaceutical industry under the new UK government.
The investigators hope that their new approach could lead to large-scale manufacturing of the CAR T cells for blood cancer patients.
The research offers insight into optimising chromatographic separation outcomes through precise control of measures such as flowrate and column length, supporting potential for drug development.
Findings from the mathematical model could support development of personalised treatments, the research suggests.
In its latest meeting, the Committee for Medicinal Products for Human Use (CHMP) recommended several new medicines, including positive opinions for treatments for rare disorders.
The GLP-1 receptor agonist demonstrated good safety and tolerability in both healthy and overweight/obese adult participants, the Phase I study found.
FDA’s new draft guidance follows the new requirement for clinical study sponsors to submit Diversity Action Plans, eg, when submitting their investigational new drug (IND) application.
Novo Nordisk plans to allocate $6.8 billion towards production to expand its overall US manufacturing capacity.
The newly authorised formulation of the anti-CD20 therapy provides certain multiple sclerosis patients with another treatment option comparable to intravenous infusion.
Large-scale platelet manufacturing must consider turbulent energy and shear stress as well as the undesired turbulent flow space within a bioreactor, the paper concluded.
SGS’s Birsfelden, Switzerland lab is now a “one-stop shop” for biopharma firms in GMP/non-GMP analytics, featuring a new stability studies capability.
According to Gilead, the study is the first Phase III HIV prevention trial to demonstrate a zero-infection rate.